Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Locally Advanced Unresectable Gastric Adenocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma 1

Interventions

pembrolizumab 6avelumab 4Magnetic Resonance Spectroscopy 2Docetaxel 2Cisplatin 2ALT-803 2yeast-CEA vaccine 1vadimezan 1trebananib 1obinutuzumab 1naptumomab estafenatox 1erdafitinib 1enfortumab vedotin 1bicalutamide 1atezolizumab 1Ultrasonography 1Specimen Handling 1Ramucirumab 1Radiosurgery 1Phantoms, Imaging 1PM 01183 1Omacor 1Nivolumab 1Neoadjuvant Therapy 1Mitomycin 1Lycopene 1Leucovorin 1High-Intensity Focused Ultrasound Ablation 1Gemcitabine 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Transitional Cell × Ramucirumab × Clear all
NCT04179110 2022-02-22

Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor

Yale University

Phase 2 Withdrawn
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡